Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - adrovance
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp21bdef881af840c0b4e754d37782a5bd
identifier: http://ema.europa.eu/identifier
/EU/1/06/364/001 – 2 tablets
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: ADROVANCE 70 mg/2,800 IU tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-21bdef881af840c0b4e754d37782a5bd
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/06/364/001 – 2 tablets
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - adrovance
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
What is ADROVANCE? ADROVANCE is a tablet containing the two active substances, alendronic acid (commonly called alendronate) and colecalciferol known as vitamin D3. What is alendronate? Alendronate belongs to a group of non-hormonal medicines called bisphosphonates. Alendronate prevents the loss of bone that occurs in women after they have been through the menopause, and helps to rebuild bone. It reduces the risk of spine and hip fractures.
What is vitamin D? Vitamin D is an essential nutrient, required for calcium absorption and healthy bones. The body can only absorb calcium properly from our food if it has enough vitamin D. Very few foods contain vitamin D. The main source is through exposure to summer sunlight, which makes vitamin D in our skin. As we get older our skin makes less vitamin D. Too little vitamin D may lead to bone loss and osteoporosis. Severe vitamin D deficiency may cause muscle weakness which can lead to falls and a greater risk of fractures.
What is ADROVANCE used for? Your doctor has prescribed ADROVANCE to treat your osteoporosis and because you are at risk of vitamin D insufficiency. It reduces the risk of spine and hip fractures in women after menopause.
What is osteoporosis? Osteoporosis is a thinning and weakening of the bones. It is common in women after the menopause. At the menopause, the ovaries stop producing the female hormone, oestrogen, which helps to keep a woman s skeleton healthy. As a result, bone loss occurs and bones become weaker. The earlier a woman reaches the menopause, the greater the risk of osteoporosis.
Early on, osteoporosis usually has no symptoms. If left untreated, however, it can result in broken bones. Although these usually hurt, breaks in the bones of the spine may go unnoticed until they cause height loss. Broken bones can happen during normal, everyday activity, such as lifting, or from minor injury that would not generally break normal bone. Broken bones usually occur at the hip, spine, or wrist and can lead not only to pain but also to considerable problems like stooped posture ( dowager s hump ) and loss of mobility.
How can osteoporosis be treated? As well as your treatment with ADROVANCE, your doctor may suggest you make changes to your lifestyle to help your condition, such as:
Stopping smoking Smoking appears to increase the rate at which you lose bone and, therefore, may increase your risk of broken bones.
Exercise Like muscles, bones need exercise to stay strong and healthy. Consult your doctor before you begin any exercise programme.
Eating a balanced diet Your doctor can advise you about your diet or whether you should take any dietary supplements.
Do not take ADROVANCE
If you think any of these apply to you, do not take the tablets. Talk to your doctor first and follow the advice given.
Warnings and precautions Talk to your doctor or pharmacist before taking ADROVANCE if:
You may be advised to have a dental check-up before starting treatment with ADROVANCE.
It is important to maintain good oral hygiene when being treated with ADROVANCE. You should have routine dental check-ups throughout your treatment and you should contact your doctor or dentist if you experience any problems with your mouth or teeth such as loose teeth, pain or swelling.
Irritation, inflammation or ulceration of the gullet (oesophagus the tube that connects your mouth with your stomach) often with symptoms of chest pain, heartburn, or difficulty or pain upon swallowing may occur, especially if patients do not drink a full glass of water and/or if they lie down less than 30 minutes after taking ADROVANCE. These side effects may worsen if patients continue to take ADROVANCE after developing these symptoms.
Children and adolescents ADROVANCE should not be given to children and adolescents less than 18 years of age.
Other medicines and ADROVANCE Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
It is likely that calcium supplements, antacids, and some oral medicines will interfere with the absorption of ADROVANCE if taken at the same time. Therefore, it is important that you follow the advice given in section 3 and wait at least 30 minutes before taking any other oral medicines or supplements.
Certain medicines for rheumatism or long-term pain called NSAIDs (e.g. acetylsalicylic acid or ibuprofen) might cause digestive problems. Therefore, caution should be used when these medicines are taken at the same time as ADROVANCE.
It is likely that certain medicines or food additives may prevent the vitamin D in ADROVANCE from getting into your body, including artificial fat substitutes, mineral oils, the weight loss medicine, orlistat, and the cholesterol-lowering medicines, cholestyramine and colestipol. Medicines for fits (seizures) (like phenytoin or phenobarbital) may decrease the effectiveness of vitamin D. Additional vitamin D supplements may be considered on an individual basis.
ADROVANCE with food and drink It is likely that food and beverages (including mineral water) will make ADROVANCE less effective if taken at the same time. Therefore, it is important that you follow the advice given in section 3. You must wait at least 30 minutes before taking any food and beverages except water.
Pregnancy and breast-feeding ADROVANCE is only intended for use in postmenopausal women. You should not take ADROVANCE if you are or think you may be pregnant, or if you are breast-feeding.
Driving and using machines There have been side effects (for example blurred vision, dizziness and severe bone, muscle or joint pain) reported with ADROVANCE that may affect your ability to drive or operate machinery (see section 4). If you experience any of these side effects you should not drive until you feel better.
ADROVANCE contains lactose and sucrose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
ADROVANCE contains sodium.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium- free .
Always take ADROVANCE exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
Take one ADROVANCE tablet once a week.
Follow these instructions carefully.
Choose the day of the week that best fits your schedule. Every week, take one ADROVANCE tablet on your chosen day.
It is very important to follow instructions 2), 3), 4) and 5) to help the ADROVANCE tablet reach your stomach quickly and help reduce the chance of irritating your gullet (oesophagus - the tube that connects your mouth with your stomach).
After getting up for the day and before taking any food, drink, or other medicine, swallow your ADROVANCE tablet whole with a full glass of water only (not mineral water) (not less than 200 ml), so that ADROVANCE is adequately absorbed.
Do not crush or chew the tablet or allow it to dissolve in your mouth because of the possibility of mouth ulceration.
Do not lie down stay fully upright (sitting, standing or walking) for at least 30 minutes after swallowing the tablet. Do not lie down until after your first food of the day.
Do not take ADROVANCE at bedtime or before getting up for the day.
If you develop difficulty or pain upon swallowing, chest pain, or new or worsening heartburn, stop taking ADROVANCE and contact your doctor.
After swallowing your ADROVANCE tablet, wait at least 30 minutes before taking your first food, drink, or other medicine of the day, including antacids, calcium supplements and vitamins. ADROVANCE is effective only if taken when your stomach is empty.
If you take more ADROVANCE than you should If you take too many tablets by mistake, drink a full glass of milk and contact your doctor immediately. Do not make yourself vomit, and do not lie down.
If you forget to take ADROVANCE If you miss a dose, just take one tablet on the morning after you remember. Do not take two tablets on the same day. Return to taking one tablet once a week, as originally scheduled on your chosen day.
If you stop taking ADROVANCE It is important that you take ADROVANCE for as long as your doctor prescribes the medicine. Since it is not known how long you should take ADROVANCE, you should discuss the need to stay on this medicine with your doctor periodically to determine if ADROVANCE is still right for you.
An Instruction Card is included in the carton for ADROVANCE. It contains important information reminding you how to take ADROVANCE properly.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
See your doctor immediately if you notice any of the following side effects, which may be serious, and for which you may need urgent medical treatment: Common (may affect up to 1 in 10 people):
Rare (may affect up to 1 in 1,000 people):
Not known (cannot be estimated from the available data):
Other side effects include Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people):
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and the blister after EXP. The expiry date refers to the last day of that month.
Store in the original blister in order to protect from moisture and light.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What ADROVANCE contains
The active substances are alendronic acid and colecalciferol (vitamin D3). Each ADROVANCE 70 mg/2,800 IU tablet contains 70 mg alendronic acid (as sodium trihydrate) and 70 micrograms (2,800 IU) colecalciferol (vitamin D3). Each ADROVANCE 70 mg/5,600 IU tablet contains 70 mg alendronic acid (as sodium trihydrate) and 140 micrograms (5,600 IU) colecalciferol (vitamin D3).
The other ingredients are microcrystalline cellulose (E460), lactose anhydrous (see section 2), medium chain triglycerides, gelatin, croscarmellose sodium, sucrose (see section 2), colloidal silicon dioxide, magnesium stearate (E572), butylhydroxytoluene (E321), modified starch (maize), and sodium aluminium silicate (E554).
What ADROVANCE looks like and contents of the pack
ADROVANCE 70 mg/2,800 IU tablets are available as modified capsule-shaped, white to off-white tablets marked with an outline of a bone image on one side and 710 on the other. ADROVANCE 70 mg/2,800 IU tablets are available in packs containing 2, 4, 6 or 12 tablets.
ADROVANCE 70 mg/5,600 IU tablets are available as modified rectangle-shaped, white to off-white tablets marked with an outline of a bone image on one side and 270 on the other. ADROVANCE 70 mg/5,600 IU tablets are available in packs containing 2, 4 or 12 tablets.
Not all pack sizes may be marketed.
Marketing Authorisation Holder N.V. Organon Kloosterstraat 6 5349 AB Oss The Netherlands Manufacturer Merck Sharp & Dohme B.V. Waarderweg 2031 BN Haarlem The Netherlands
Organon Heist bv Industriepark 2220 Heist-op-den-Berg Belgium
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.
Belgi /Belgique/Belgien Organon Belgium T l/Tel: 0080066550123 (+32 2 2418100)
dpoc.benelux@organon.com
Lietuva Organon Pharma B.V. Lithuania atstovyb
Tel.: +370 52041dpoc.lithuania@organon.com
( . .) . . -
.: +359 2 806 3dpoc.bulgaria@organon.com
Luxembourg/Luxemburg
Organon Belgium T l/Tel: 0080066550123 (+32 2 2418100)
dpoc.benelux@organon.com
esk republika Organon Czech Republic s.r.o. Tel: +420 233 010 dpoc.czech@organon.com
Magyarorsz g Organon Hungary Kft. Tel.: +36 1 766 1dpoc.hungary@organon.com
Danmark Organon Denmark ApS
Tlf: +45 4484 6info.denmark@organon.com
Malta Organon Pharma B.V., Cyprus branch Tel: +356 2277 8dpoc.cyprus@organon.com
Deutschland Organon Healthcare GmbH Tel: 0800 3384 726 (+49 (0) 89 2040022 10)
dpoc.germany@organon.com
Nederland N.V. Organon Tel.: 00800 66550123 (+32 2 2418100) dpoc.benelux@organon.com
Eesti Organon Pharma B.V. Estonian RO Tel: +372 66 61 dpoc.estonia@organon.com
Norge Organon Norway AS Tlf: +47 24 14 56 info.norway@organon.com
E
N.V. Organon : +30-216 6008 sterreich Organon Healthcare GmbH
Tel: +49 (0) 89 2040022 dpoc.austria@organon.com Espa a Organon Salud, S.L. Tel: +34 91 591 12 organon_info@organon.com
Polska Organon Polska Sp. z o.o. Tel.: +48 22 105 50 organonpolska@organon.com
France Organon France
T l: +33 (0) 1 57 77 32 Portugal Organon Portugal, Sociedade Unipessoal Lda. Tel: +351 218705geral_pt@organon.com
Hrvatska Organon Pharma d.o.o. Tel: +385 1 638 4dpoc.croatia@organon.com
Rom nia Organon Biosciences S.R.L. Tel: +40 21 527 29 dpoc.romania@organon.com Ireland Organon Pharma (Ireland) Limited Tel: +353 15828medinfo.ROI@organon.com
Slovenija Organon Pharma B.V., Oss, podru nica Ljubljana Tel: +386 1 300 10 dpoc.slovenia@organon.com
sland Vistor hf. S mi: +354 535 7Slovensk republika Organon Slovakia s. r. o. Tel: +421 2 44 88 98 dpoc.slovakia@organon.com
talia Addenda Pharma S.r.l.,
Tel: +39-06-9139 3addendapharma@legalmail.it
Suomi/Finland Organon Finland Oy Puh/Tel: +358 (0) 29 170 3dpoc.finland@organon.com
Organon Pharma B.V., Cyprus branch : +357 22866dpoc.cyprus@organon.com
Sverige Organon Sweden AB Tel: +46 8 502 597 dpoc.sweden@organon.com
Latvija rvalsts komersanta Organon Pharma B.V.
p rst vniec ba Tel: +371 66968dpoc.latvia@organon.com
United Kingdom (Northern Ireland) Organon Pharma (UK) Limited
Tel: +44 (0) 208 159 3medicalinformationuk@organon.com
This leaflet was last revised in <{MM/YYYY}>
Detailed information on this medicine is available on the European Medicines Agency website: https://www.ema.europa.eu.
Entry 1 - fullUrl = Composition/composition-en-21bdef881af840c0b4e754d37782a5bd
Resource Composition:
Generated Narrative: Composition composition-en-21bdef881af840c0b4e754d37782a5bd
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/06/364/001 – 2 tabletsstatus: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - adrovance
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp21bdef881af840c0b4e754d37782a5bd
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp21bdef881af840c0b4e754d37782a5bd
identifier:
http://ema.europa.eu/identifier
/EU/1/06/364/001 – 2 tabletstype: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: ADROVANCE 70 mg/2,800 IU tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en